PolyQ扩增突变的Ataxin-3通过调控PPARδ参与脊髓小脑共济失调3型的分子机制研究
批准号:
82101491
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
唐秘博
依托单位:
学科分类:
神经退行性变及相关疾病
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
唐秘博
中文摘要
脊髓小脑共济失调3型(SCA3)是最常见的神经遗传变性疾病之一,探讨其机制意义重大。PPARδ是近年发现的PPAR新亚型,在神经系统疾病中研究尚少。我们前期发现PPARδ在小脑中含量丰富,对线粒体及能量生成影响巨大。最近我们发现PPARδ在由Ataxin-3的PolyQ扩增突变所致的SCA3中明显降低,但具体机制不明。既往研究显示:PolyQ扩增突变的Ataxin-3能够通过转录或相互作用异常影响多种蛋白的含量及功能。我们推测:PolyQ突变的Ataxin-3通过干扰或相互作用异常影响PPARδ的功能及线粒体产生,参与SCA3的发生。本课题组已繁育SCA3转基因小鼠,完成SCA3患者来源的iPSC重编程并能够诱导分化为神经元。本研究拟应用上述疾病模型,从分子、细胞、动物等多层次探讨PolyQ突变型Ataxin-3调控PPARδ参与SCA3的可能分子机制,为阐明SCA3的发病机制提供新思路。
英文摘要
Spinocerebellar ataxia type 3 (SCA3) is one of the most common neurodegenerative disorders. Further exploration of pathogenesis underlying SCA3 is of great significance. PPARδ was discovered in recent years as one subtype of PPARs, which was lack of investigation in neurological diseases. Currently, our group reported that PPARδ was superiorly abundant in brains of wild mice and played an important role in regulating energy production, while in SCA3 disease model caused by PolyQ expansion of Ataxin-3 our preliminary work found PPARδ was significantly reduced. However, the specific molecular mechanism remains unclear. Moreover, it is reported that PolyQ expansion Ataxin-3 affects the expression and function of many proteins through abnormal transcription or interaction. Based on the above results, we hypothesize that PolyQ expansion Ataxin-3 affects the function of mitochondria by regulating PPARδ, and then participates in the occurrence of SCA3. Our group has established the SCA3 transgenic mice and completed the identification and breeding, as well as patient-derived iPSC reprogramming and neurons induction. The current study aims to apply the above disease models from molecular, cellular and animal aspects to explore the possible mechanisms of PolyQ expansion Ataxin-3 via regulating PPARδ in SCA3. This study will provide novel ideas for further elucidating the mechanisms of SCA3.
脊髓小脑共济失调3型(Spinocerebellar ataxia type 3,SCA3),又称马查多·约瑟夫病(Machado-Joseph disease,MJD)是我国遗传性共济失调中最常见的临床类型,目前本病尚无有效的治疗药物。探索SCA3的发病机制及寻找有效的治疗方法一直是该领域亟待解决的关键问题。目前本病具体发病机制尚未得到明确阐述,但线粒体的功能障碍及伴随的能量供应失调在SCA3及多种PolyQ扩增所致神经退行性疾病中已得到证实。我们前期发现PPARδ在小脑中含量丰富,对线粒体及能量生成影响巨大。本研究以SCA3转基因小鼠、SCA3患者来源的皮肤成纤维细胞及神经元为主要研究对象,运用单细胞测序、免疫共沉淀、免疫荧光、免疫印迹、腺相关病毒过表达、小分子化合物激动剂等技术方法从动物、细胞、分子层面揭示了SCA3的病理变化、PPARδ参与SCA3发病的机制及对该疾病的治疗可能提供的潜在治疗策略。本项目目前结果显示,与野生组相比,SCA3患者来源的皮肤成纤维细胞及SCA3转基因小鼠模型中的PPARδ的蛋白水平是明显降低的,PPAR水平的降低主要是由于PPAR与CAG扩增突变的ATXN3共定位于包涵体内形成不溶性蛋白蛋白导致的。上调PPARδ能够明显增加SCA3相关细胞的线粒体含量、改善SCA3细胞的病理变化。FDA 批准用于治疗 T 细胞皮肤淋巴瘤的RXR 激动剂 Bexarotene,能够通过间接激活PPARδ 改善SCA3细胞及动物的病理变化,减缓SCA3小鼠的行为学改变,对SCA3具有明显的保护作用。最后该研究应用单细胞测序技术进一步发现了参与SCA3病理变化过程中的主要细胞及分子过程。本项目的完成为揭示SCA3的发病机制及可能的治疗策略提供了新的潜在方法,为后续研究奠定了基础提供了思路。
国内基金
海外基金